Expressnews
Chennai, March 20, 2026: MV Hospital for Diabetes, Chennai, is hosting MVCON 2026, a three-day national conference from March 20 to 22, 2026, bringing together leading experts in diabetes care, research, and clinical practice.
The conference, inaugurated today, aims to promote the latest advances in diabetes management, particularly in addressing complications affecting vital organs such as the kidney, eye, and heart, along with dedicated sessions on diabetic foot care. The conference will also include live hands-on workshops, offering practical training in debridement, advanced wound care techniques, and Negative Pressure Wound Therapy. Additional sessions will cover live diabetic foot workshops, imaging, and revascularisation techniques.
The event featured the presentation of the MV Lifetime Achievement Award to Hon’ble Union Minister Dr. Jitendra Singh, an internationally renowned diabetologist and Professor of Diabetes and Endocrinology, for his contributions to diabetes research in India. He is currently serving as the Union Minister of State (Independent Charge) for Science & Technology; Earth Sciences; and Minister of State in PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space.
MVCON 2026 will also witness the presentation of the MV Lifetime Achievement Award to Mr. A. V. Anoop, for his contributions to healthcare and wellness initiatives as the Managing Director of the AVA Group, which owns the iconic Medimix brand and plays a significant role in promoting traditional and holistic healthcare practices in the country.
The scientific sessions at MVCON 2026 will feature symposiums, panel discussions, debates, quiz competitions, and oral and poster presentations. The highlights of the event include the Prof. MV Gold Medal Oration 2026 by Dr. Ashok Kumar Das, Chairman of the Academic Committee of the National Academy of Medical Sciences, New Delhi, and former Professor and Head of Endocrinology at JIPMER and PIMS, Puducherry, who has also served as Director of the Indian Institute of Diabetes, Thiruvananthapuram.
In his acceptance speech Dr. Jitendra Singh said that he feels deeply indebted to Tamil Nadu and felt extremely honoured to receive the MV lifetime achievement award 2026 and also encouraged young professionals to contribute to advancements in research and patient care among people with diabetes. Earlier, Dr. S.N. Narasingan delivered the welcome address while Dr. Prashanth Arun proposed a vote of thanks on the occasion.
Over 1,000 participants, including doctors and healthcare professionals, researchers in diabetes care, and specialists in diabetic foot and wound management are expected to attend the event. About 100 experts including, Dr. Vijay Viswanathan, Head and Chief Diabetologist, Dr Viswanathan Vishnu Vijay, Chief Executive Officer, and Dr. Prashanth Arun, Physician & Diabetologist, MV Hospital for Diabetes, are scheduled to share insights on advances in diabetes care.
Speaking about the conference, Dr. Viswanathan Vishnu Vijay said, “MVCON 2026 marks the first edition of MV’s annual scientific update. It has been conceptualised as a multidisciplinary platform that reflects the evolving nature of diabetes care. By bringing together different specialties, we aim to improve outcomes, particularly in preventing complications such as diabetic foot, which require coordinated and timely intervention. A key focus of the conference is diabetic foot disease, one of the most serious yet preventable complications of diabetes. The scientific program emphasises a comprehensive approach, not only treating diabetes but actively preventing its complications through early intervention, advanced care, and coordinated clinical practice. Experts will also explore the integration of AI and digital health, advanced therapeutics, and multidisciplinary care, with a focus on preventing complications rather than just treating diabetes.”
Major research themes at the conference include diabetic foot ulcer innovations, cardiovascular and renal complications, metabolic disorders, epigenetics, microbiota, and emerging therapies, along with topics such as diabetic retinopathy technology, chronic kidney disease in diabetes, gestational diabetes, obesity and diabesity, and cardiovascular risk.
